Quantcast
Last updated on April 18, 2014 at 7:29 EDT

Latest Bioethics Stories

Multiple Sclerosis May Benefit From Statins
2014-03-19 10:09:06

Brett Smith for redOrbit.com - Your Universe Online At first, multiple sclerosis is recognized by sporadic neurological symptoms – a condition called relapsing-remitting MS. Within a decade or so, greater than 50 percent of patients acquire secondary progressive MS, a continuous deterioration of symptoms and boost in disability. Currently, there are no approved drugs for treating this later stage of the disease. However, a newly published study in the UK medical journal The Lancet has...

Are Your Pets Benefiting From Their Pain Medication?
2014-03-13 15:17:15

Tracey Peake, North Carolina State University How do you know that your pet is benefiting from its pain medication? A new clinical trial design could help overcome pet owners’ unconscious observation bias and determine whether the drugs they test are effective. When animals are recruited for clinical trials, particularly for pain medications, researchers must rely on owner observation to determine whether the medication is working. Sounds simple enough, but as it turns out, human and...

2014-03-11 23:33:04

Achieve is conducting a phase II, placebo-controlled, multi dose, 24-week clinical study to evaluate the efficacy and safety of a new autoimmune medication in participants living with systemic lupus erythematosus (SLE). Birmingham, Alabama (PRWEB) March 11, 2014 *To see if you qualify for this Lupus Clinical Trial in Birmingham, visit Achieve Clinical Research on the web (http://www.achieveclinical.com/) or contact us directly at (205) 380-6434. There is no cost to participate, no...

2014-03-09 23:02:12

Panel of experts seeks to answer the complex legal, bioethical and medical issues raised by costly advances in drug development and research. New York, NY (PRWEB) March 09, 2014 Linda A. Malek, Chair of the Healthcare Practice at Moses & Singer LLP participated in a panel on “The Rising Cost of Cancer Drugs and Cancer Research” at the New York City Bar Association on March 6, 2014. The program was sponsored by the Bioethical Issues Committee and moderated by renowned bioethicist...

2014-03-07 23:22:43

Art Caplan will discuss "End of Life: Legal, Medical and Ethical Issues" for the annual Batdorf Lecture at Alvernia University, March 18, 2014. Reading, PA (PRWEB) March 07, 2014 Art Caplan, considered one of the foremost experts on Bioethics and the ethics of healthcare reform, will discuss the legal, medical and ethical issues surrounding end of life for Alvernia University’s annual Batdorf Lecture, March 18, 5 p.m., in the McGlinn Conference Center. The lecture will be...

2014-03-05 08:20:33

Hawaii Biotech Receives DoD Contract to Develop Anti-Botulism Drug HONOLULU, March 5, 2014 /PRNewswire/ -- The Department of Defense, Defense Threat Reduction Agency, has awarded Hawaii Biotech, Inc., a contract to continue developing drugs to block botulinum toxin, the toxin that causes the life-threatening disease, botulism. There is no therapeutic drug currently available for the treatment of botulism. The award has a first-year period of performance through early 2014, followed...

2014-03-03 08:31:20

6.8% improvement in FEV1 versus placebo in high FENO subset representing half of treated patients BOULDER, Colo., March 3, 2014 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY) reported full results from a randomized Phase 2 trial of ARRY-502 in patients with mild to moderate Th2-Driven Asthma at the 2014 American Academy Of Allergy, Asthma & Immunology (AAAAI) Annual Meeting. http://photos.prnewswire.com/prnvar/20121029/LA02195LOGO ARRY-502, an oral CRTh2 antagonist, was studied in a...

2014-02-25 08:31:00

- Study Meets Primary and Both Key Secondary Endpoints - BRISBANE, Calif., Feb. 25, 2014 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced that top-line data from ASCEND, a Phase 3 trial evaluating pirfenidone in patients with idiopathic pulmonary fibrosis (IPF), demonstrated that pirfenidone significantly reduced IPF disease progression as measured by change in percent predicted forced vital capacity (FVC) from Baseline to Week 52 (rank ANCOVA p<0.000001)....

2014-02-18 08:29:35

MELBOURNE, Australia and NEW YORK, Feb. 18, 2014 /PRNewswire/ -- Key Points: -- Primary endpoints of safety and tolerability met. -- Secondary endpoint: Statistically significant improvement in a measure of executive function(cognition) in research participants administered 250mg PBT2 daily (p=0.042). -- PBT2 250mg was also associated with a favourable signal in functional capacity. -- Preliminary evidence suggests PBT2 250mg reduced atrophy of...

2014-02-14 23:01:28

Results from Alpha BRAIN™ Pilot Study to Be Presented at the International Neuropsychological Society Annual Conference Austin, Texas (PRWEB) February 14, 2014 Results from a pilot study entitled “A Proof of Concept Study for a Randomized Double-Blind, Placebo Controlled, Parallel Group, Efficacy Study of Alpha BRAIN™ Administered Orally,” conducted by the Boston Center for Memory will be presented at the annual International Neuropsychological Society (INS) meeting in Seattle,...


Latest Bioethics Reference Libraries

OncoMouse
2013-10-02 09:29:43

The OncoMouse or Harvard Mouse is a type of laboratory mouse that has been genetically modified utilizing modification designed by Philip Leder and Timothy A. Stewart, of Harvard University, to carry a certain gene called an activated oncogene. The activated oncogene considerably increases the mouse’s vulnerability to cancer, therefore making the mouse suitable for cancer research. The rights to the invention were owned by DuPont until recently. The USPTO found that the patent expired in...

More Articles (1 articles) »